Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Olympus Yönetim

Yönetim kriter kontrolleri 1/4

Olympus' CEO'su Stefan Kaufmann, Apr2023 tarihinde atandı, in görev süresi 1.5 yıldır. in toplam yıllık tazminatı ¥ 1.14B olup, şirket hissesi ve opsiyonları dahil olmak üzere 53.3% maaş ve 46.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.015% ine doğrudan sahiptir ve bu hisseler ¥ 465.58M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.5 yıl ve 3.3 yıldır.

Anahtar bilgiler

Stefan Kaufmann

İcra Kurulu Başkanı

JP¥1.1b

Toplam tazminat

CEO maaş yüzdesi	53.3%
CEO görev süresi	1.5yrs
CEO sahipliği	0.01%
Yönetim ortalama görev süresi	1.5yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Stefan Kaufmann'un ücretlendirmesi Olympus'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	JP¥28b
Mar 31 2024	JP¥1b	JP¥607m	JP¥27b
Dec 31 2023	n/a	n/a	JP¥39b
Sep 30 2023	n/a	n/a	JP¥57b
Jun 30 2023	n/a	n/a	JP¥126b
Mar 31 2023	n/a	n/a	JP¥138b
Dec 31 2022	n/a	n/a	JP¥138b
Sep 30 2022	n/a	n/a	JP¥127b
Jun 30 2022	n/a	n/a	JP¥122b
Mar 31 2022	JP¥661m	JP¥472m	JP¥116b
Dec 31 2021	n/a	n/a	JP¥95b
Sep 30 2021	n/a	n/a	JP¥98b
Jun 30 2021	n/a	n/a	JP¥84b
Mar 31 2021	n/a	n/a	JP¥66b
Dec 31 2020	n/a	n/a	JP¥46b
Sep 30 2020	n/a	n/a	JP¥41b
Jun 30 2020	n/a	n/a	JP¥43b
Mar 31 2020	JP¥206m	JP¥158m	JP¥52b

Tazminat ve Piyasa: Stefan 'nin toplam tazminatı ($USD 7.92M ), JP pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.46M ).

Tazminat ve Kazançlar: Stefan şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.

CEO

Stefan Kaufmann (56 yo)

1.5yrs

Görev süresi

JP¥1,138,000,000

Tazminat

Mr. Stefan Kaufmann serves as Director and Representative Executive Officer of Olympus Corporation since June 2019 and April 2023 respectively and had been its Executive Officer since June 2019 until April...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yasuo Takeuchi	Representative Executive Officer	12.5yrs	JP¥497.00m	0.022% ¥ 683.9m
Stefan Kaufmann	Representative Executive Officer	1.5yrs	JP¥1.14b	0.015% ¥ 465.1m
Andre Roggan	Executive Officer & CTO	2.5yrs	JP¥462.00m	0.0022% ¥ 69.2m
Tetsuo Kobayashi	Executive Officer and Chief Manufacturing & Supply Officer	no data	JP¥119.00m	0.0036% ¥ 113.5m
Frank Drewalowski	Executive Officer & Endoscopic Solutions Division Head	4.8yrs	JP¥459.00m	0.0013% ¥ 39.9m
Gabriela Kaynor	Executive Officer & Chief Strategy Officer	no data	JP¥218.00m	0.00046% ¥ 14.5m
Tatsuya Izumi	Executive Officer & CFO	less than a year	Veri yok	Veri yok
Stephen Kneebone	Corporate Officer & Chief Information Officer	2.8yrs	JP¥734.00m	Veri yok
Takaaki Sakurai	Vice President of Investor Relations	no data	Veri yok	Veri yok
Eva Gardyan-Eisenlohr	Chief Compliance Officer	less than a year	Veri yok	Veri yok
Neil Tanner	Executive Officer & Global General Counsel	less than a year	Veri yok	Veri yok
Shigeto Ohtsuki	Executive Officer & Chief Human Resources Officer	4.8yrs	Veri yok	0.00058% ¥ 18.2m

1.5yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim: 7733 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.5 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yasuo Takeuchi	Representative Executive Officer	12.5yrs	JP¥497.00m	0.022% ¥ 683.9m
Stefan Kaufmann	Representative Executive Officer	5.3yrs	JP¥1.14b	0.015% ¥ 465.1m
Sumitaka Fujita	Independent Outside Director	12.5yrs	Veri yok	0.0017% ¥ 54.4m
Jimmy C. Beasley	Independent Outside Director	5.3yrs	Veri yok	0.00052% ¥ 16.4m
Gary John Pruden	Independent Outside Director	2.3yrs	Veri yok	0.00040% ¥ 12.6m
Masato Iwasaki	Independent Outside Director	less than a year	Veri yok	Veri yok
David Robert Hale	Independent Outside Director	5.3yrs	Veri yok	Veri yok
Luann Marie Pendy	Independent Outside Director	1.3yrs	Veri yok	0.00031% ¥ 9.7m
Toshihiko Okubo	Director	1.3yrs	Veri yok	0.0022% ¥ 67.9m
Sachiko Ichikawa	Independent Outside Director	3.3yrs	Veri yok	0.00062% ¥ 19.5m
Kohei Kan	Independent Outside Director	2.3yrs	Veri yok	0.00065% ¥ 20.4m

3.3yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 7733 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Olympus Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Olympus Corporation Announces Executive Changes, Effective October 1, 2024

High number of new directors

High number of new directors

Olympus Corporation, Annual General Meeting, Jun 26, 2024

Olympus Corporation Announces Executive Changes

Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer

Recent updates

A Look At The Intrinsic Value Of Olympus Corporation (TSE:7733)

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Olympus Corporation Announces Executive Changes, Effective October 1, 2024

High number of new directors

Does Olympus (TSE:7733) Have A Healthy Balance Sheet?

Now 22% overvalued after recent price rise

Estimating The Fair Value Of Olympus Corporation (TSE:7733)

High number of new directors

Olympus Corporation, Annual General Meeting, Jun 26, 2024

Olympus Corporation (TSE:7733) announces an Equity Buyback for 60,000,000 shares, representing 5.15% for ¥100,000 million.

Slowing Rates Of Return At Olympus (TSE:7733) Leave Little Room For Excitement

Olympus Corporation to Report Q1, 2025 Results on Aug 07, 2024

Upcoming dividend of JP¥18.00 per share

Olympus Corporation's (TSE:7733) Share Price Matching Investor Opinion

Dividend of JP¥18.00 announced

Olympus Corporation Revises Consolidated Revenue Guidance for the Fiscal Year Ending March 31, 2024

New minor risk - Earnings quality

Olympus Corporation Announces Executive Changes

Olympus Corporation (TSE:7733) completed the acquisition of Taewoong Medical Co. Ltd. from Kyong-min Shin and others.

Now 21% overvalued after recent price rise

Olympus Corporation Announces Study Results Show the S Sustained Clinical Benefits of Spiration Valve System At 24 Months

Olympus Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Olympus Corporation (TSE:7733) announces an Equity Buyback for 53,000,000 shares, representing 4.34% for ¥80,000 million.

Olympus Corporation Announces Market Launch of EVIS X1 Endoscopy System

Olympus Corporation Announces the Launch of the Vathin E-SteriScope

Investor sentiment deteriorates as stock falls 16%

New minor risk - Share price stability

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Olympus Corporation Announces Publication of Study Data Demonstrating That the Minimally Invasive Itind™? Treatment Provides Long-Lasting Relief of More Than Four Years

Olympus Corporation to Report Q3, 2024 Results on Feb 14, 2024

Full year 2023 earnings: EPS misses analyst expectations

Olympus Corporation Reiterates Consolidated Financial Guidance for the Fiscal Year Ending March 2024

Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 38%

Olympus Corporation, Annual General Meeting, Jun 27, 2023

Now 21% undervalued after recent price drop

Olympus Corporation Set to Demonstrate Newest Endoscopy System At DDW

Now 21% undervalued

Consensus EPS estimates increase by 79%

Consensus EPS estimates fall by 61%

Upcoming dividend of JP¥16.00 per share at 0.7% yield

Third quarter 2023 earnings released: EPS: JP¥28.43 (vs JP¥19.66 in 3Q 2022)

Olympus Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2023 earnings released

Second quarter 2023 earnings released

Olympus Corporation (TSE:7733) announces an Equity Buyback for 21,000,000 shares, representing 1.65% for ¥50,000 million.

Olympus Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Olympus Launches VISERA ELITE III Surgical Visualization Platform

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Bain Capital Private Equity, LP entered into a definitive agreement to acquire Scientific Solutions Business of Olympus Corporation from Olympus Corporation (TSE:7733) for approximately JPY 427.67 billion.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Olympus Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

High number of new directors

Olympus Announces the Availability of New Monitor Option, the OEV321UH Video Display Monitor

Full year 2022 earnings: Revenues in line with analyst expectations

Olympus Corporation Announces Study Results Show Long-Term Efficacy of Itind Procedure

Investor sentiment improved over the past week

Olympus Corporation to Report Q3, 2023 Results on Feb 10, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Olympus Corporation Announces Dividend for the Year Ended March 31, 2022, Payable on June 3, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

High number of new directors

Olympus Corporation to Report Fiscal Year 2022 Results on May 11, 2022

Upcoming dividend of JP¥14.00 per share

Now 21% undervalued after recent price drop